Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Products under Development by Stage of Development | 10 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Products under Development by Therapy Area | 11 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Products under Development by Indication | 12 | 2 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Pipeline Products Glance | 14 | 2 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Products under Development by Companies | 16 | 4 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Therapeutics Assessment | 20 | 5 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Companies Involved in Therapeutics Development | 25 | 16 |
| Aclaris Therapeutics, Inc. | 25 | 1 |
| Advinus Therapeutics Ltd | 26 | 1 |
| Arrien Pharmaceuticals, LLC | 27 | 1 |
| Astellas Pharma Inc. | 28 | 1 |
| Bristol-Myers Squibb Company | 29 | 1 |
| Chipscreen Biosciences Ltd | 30 | 1 |
| Creabilis SA | 31 | 1 |
| F. Hoffmann-La Roche Ltd. | 32 | 1 |
| Ligand Pharmaceuticals, Inc. | 33 | 1 |
| MYOS RENS Technology Inc. | 34 | 1 |
| Pfizer Inc. | 35 | 1 |
| Portola Pharmaceuticals, Inc. | 36 | 1 |
| Principia Biopharma Inc. | 37 | 1 |
| Rigel Pharmaceuticals, Inc. | 38 | 1 |
| Theravance Biopharma, Inc. | 39 | 1 |
| Vectura Group Plc | 40 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Drug Profiles | 41 | 37 |
| ARN-4079 Drug Profile | 41 | 1 |
| ATI-50001 Drug Profile | 42 | 1 |
| ATI-50002 Drug Profile | 43 | 1 |
| cerdulatinib Drug Profile | 44 | 4 |
| CS-510 Drug Profile | 48 | 1 |
| CS-944X Drug Profile | 49 | 1 |
| CT-340 Drug Profile | 50 | 1 |
| Drug to Inhibit JAK3 for Inflammation Drug Profile | 51 | 1 |
| peficitinib hydrobromide Drug Profile | 52 | 2 |
| PNQ-401 Drug Profile | 54 | 1 |
| R-348 Drug Profile | 55 | 2 |
| Small Molecule to Inhibit JAK3 for Heart Transplantation Drug Profile | 57 | 1 |
| Small Molecule To Inhibit JAK3 for Rheumatoid Arthritis Drug Profile | 58 | 1 |
| Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases Drug Profile | 59 | 1 |
| Small Molecules to Inhibit JAK3 for Alopecia and Dermatological Disorders Drug Profile | 60 | 1 |
| Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis Drug Profile | 61 | 1 |
| Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia Drug Profile | 62 | 1 |
| Small Molecules to Inhibit Janus Kinase 3 for Inflammation Drug Profile | 63 | 1 |
| TD-1473 Drug Profile | 64 | 1 |
| tofacitinib citrate Drug Profile | 65 | 12 |
| VR-588 Drug Profile | 77 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Dormant Projects | 78 | 4 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Discontinued Products | 82 | 1 |
| Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Featured News &Press Releases | 83 | 16 |
| Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor | 83 | 1 |
| Jun 08, 2016: Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ) Providing Clinicians With Additional Information For The Treatment Of Moderate To Severe RA | 84 | 2 |
| Jun 07, 2016: Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis | 86 | 1 |
| Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings | 87 | 1 |
| Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 | 88 | 1 |
| Apr 05, 2016: Pfizer Announces Positive Top-Line Results From The First Phase 3 Trial Of Investigational Tofacitinib In Adults With Psoriatic Arthritis | 88 | 1 |
| Mar 23, 2016: Pfizer Announces European Medicines Agency Accepted For Review Its Marketing Authorization Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Moderate To Severe Rheumatoid Arthritis | 89 | 1 |
| Mar 18, 2016: Pfizer Announces Oral Tofacitinib, An Investigational Jak Inhibitor, Meets Primary And Key Secondary Endpoints In Two Pivotal Phase 3 Ulcerative Colitis Trials | 90 | 1 |
| Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor | 91 | 1 |
| Mar 16, 2016: Pfizer To Present New Data On Investigational Tofacitinib In Inflammatory Bowel Disease At The 11th Congress Of ECO | 92 | 1 |
| Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor | 93 | 1 |
| Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor | 94 | 1 |
| Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition | 94 | 1 |
| Nov 02, 2015: New Data Continue to Characterize the Safety and Efficacy of XELJANZ in the Treatment of Rheumatoid Arthritis | 95 | 3 |
| Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor | 98 | 1 |
| Appendix | 99 | 2 |
| Methodology | 99 | 1 |
| Coverage | 99 | 1 |
| Secondary Research | 99 | 1 |
| Primary Research | 99 | 1 |
| Expert Panel Validation | 99 | 1 |
| Contact Us | 99 | 1 |
| Disclaimer | 100 | 1 |